[go: up one dir, main page]

MX2010002300A - Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl ) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same. - Google Patents

Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl ) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same.

Info

Publication number
MX2010002300A
MX2010002300A MX2010002300A MX2010002300A MX2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A MX 2010002300 A MX2010002300 A MX 2010002300A
Authority
MX
Mexico
Prior art keywords
sulfonyl
hydrate
pyridine
tert
benzyl
Prior art date
Application number
MX2010002300A
Other languages
Spanish (es)
Inventor
Joseph Francis Krzyzaniak
David Burns Damon
Jinyang Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2010002300A publication Critical patent/MX2010002300A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to polymorphic crystalline forms or a non- crystalline form or amorphous of the compound (3-(((4-tert-butyl-benzyl)-(pyridine- 3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof together with processes for preparing, methods for using, and pharmaceutical compositions containing the same. The invention also relates to substantially pure polymorphic crystalline forms or a non-crystalline form or amorphous form of (3- (((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-ph enoxy)-acetic acid sodium salt or a hydrate thereof.
MX2010002300A 2007-08-29 2008-08-25 Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl ) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same. MX2010002300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96877107P 2007-08-29 2007-08-29
US8355908P 2008-07-25 2008-07-25
PCT/IB2008/002252 WO2009027811A2 (en) 2007-08-29 2008-08-25 Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same

Publications (1)

Publication Number Publication Date
MX2010002300A true MX2010002300A (en) 2010-03-18

Family

ID=40042625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002300A MX2010002300A (en) 2007-08-29 2008-08-25 Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl ) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same.

Country Status (9)

Country Link
EP (1) EP2185516A2 (en)
JP (1) JP2009137934A (en)
KR (1) KR20100050559A (en)
CN (1) CN101842356A (en)
AR (1) AR068349A1 (en)
AU (1) AU2008291814A1 (en)
CA (1) CA2697950A1 (en)
MX (1) MX2010002300A (en)
WO (1) WO2009027811A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104478868A (en) * 2009-02-27 2015-04-01 奥索-麦克尼尔-詹森药品公司 Amorphous salt of a macrocyclic inhibitor of HCV
TWI762770B (en) * 2018-02-28 2022-05-01 韓商畢利吉生物科技股份有限公司 Water soluble salts of lipidated peptides and methods for preparing and using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders

Also Published As

Publication number Publication date
AU2008291814A1 (en) 2009-03-05
AR068349A1 (en) 2009-11-11
EP2185516A2 (en) 2010-05-19
CA2697950A1 (en) 2009-03-05
KR20100050559A (en) 2010-05-13
JP2009137934A (en) 2009-06-25
WO2009027811A2 (en) 2009-03-05
CN101842356A (en) 2010-09-22
WO2009027811A3 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2007141283A3 (en) Salts and crystalline salt forms of an 2-indolinone derivative
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
MX2012013332A (en) Preparation of posaconazole intermediates.
WO2012138147A3 (en) 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof
MX2009003257A (en) Process for synthesis of phenoxy diaminopyrimidine derivatives.
WO2013014665A8 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
MX2011007978A (en) Novel method for the synthesis of ivabradine and the pharmaceutically acceptable acid addition salts thereof.
MX2011009898A (en) Process for the preparation of propionic acid derivatives.
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EA201300647A1 (en) OPTIMIZED SYNTHESIS OF PURE NONPOLYMORPHIC CRYSTALLINE YELLOW ACIDS WITH A PARTICLE SIZE
MX2009005911A (en) Crystalline potassium salt of lipoxin a4 analogs.
MX2010003213A (en) Novel method for the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid.
WO2008117305A3 (en) A novel process for preparing pregabalin and its acid addition salts
WO2010079045A3 (en) Crystalline salt forms of flibanserine
MX2012002818A (en) Novel method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid.
WO2011008666A3 (en) 3-phenoxymethylpyrrolidine compounds
WO2008015703A3 (en) Process for the preparation of montelukast and its salts thereof
MX2010009926A (en) New process for the preparatiion of cyclohexanecarboxylic acid dericatives.
WO2008081476A3 (en) Process for preparing duloxetine hydrochloride
MX337997B (en) New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid.
WO2011135586A3 (en) Process for the preparation of chiral beta amino carboxamide derivatives
MX2010002300A (en) Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl ) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal